Stock Chart

MYGN

$5.47 -2.67%
Score: 49.0 HOLD
1Y Target $5.17 -5.5%
i
1Y Price Target

This target is derived from long-term trendline analysis and projected growth.

Note: Targets are based on the assumption that the current primary trend continues. They should be used as reference points, not guarantees.

Target may adjust dynamically as the stock trend reverses or accelerates.
LEAPs: SELL $8
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $8
Premium: $0.76
Expiry: May 15, 2026
Target: $8
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $4.59 - $5.28 STRONG_DOWNTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.61
Vol: 0.87x (vs SPY: 0.9x | vs QQQ: 1.0x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About MYGN - Myriad Genetics Inc

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines …

Key Statistics

Market Cap $524M

This MYGN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track MYGN's price movements with trendlines, gamma walls, and key support/resistance levels.